U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
PR Newswire•18/09/2026•13:54 ET
0
Get started
Create a free account to read the full story and Whiz Insights.